Delving into the Latest Updates on Enzalutamide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Enolen, Enzalutamide (JAN/USAN), 恩杂鲁胺

+ [9]

Target

AR

Action

antagonists

Mechanism

AR antagonists(Androgen Receptor antagonists)

Therapeutic Areas

NeoplasmsUrogenital DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Prostatic CancerCastration-sensitive prostate cancerHRR Gene-mutated Castration-Resistant Prostate Cancer+ [12]

Inactive Indication

Advanced Hepatocellular CarcinomaAdvanced Prostate CarcinomaAdvanced Triple-Negative Breast Carcinoma+ [22]

Originator Organization

Medivation LLC (California)

Active Organization

Medivation LLC (California)

Pfizer Inc.MediVation, Inc.

+ [13]

Inactive Organization

Oric Pharmaceuticals, Inc.

Kangpu Biopharmaceuticals Ltd.

License Organization

Nektar Therapeutics

Medivation LLC (California)

Oric Pharmaceuticals, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (31 Aug 2012),

Metastatic castration-resistant prostate cancer

RegulationFast Track (United States), Priority Review (Canada), Priority Review (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC21H16F4N4O2S

InChIKeyWXCXUHSOUPDCQV-UHFFFAOYSA-N

CAS Registry915087-33-1

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Start Date31 Mar 2026

Sponsor / Collaborator

Roche Holding AG

NCT06616155

/ RecruitingPhase 1/2IIT

Study of JAK Inhibition in Stem-Like Prostate Cancer (JASPER): A Phase 1b/2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resistant) and that has spread from where it first started to other places in the body (metastatic). Ruxolitinib, a kinase inhibitor, slows down the growth of the tumor by blocking the proteins, JAK1 and JAK2, tumors use to grow. Enzalutamide, an androgen receptor inhibitor, works by blocking the effects of androgen (a male reproductive hormone). This may help stop the growth and spread of tumor cells that need testosterone to grow. Giving ruxolitinib in combination with enzalutamide may be safe, tolerable, and/or effective in treating metastatic castration-resistant prostate cancer.

Start Date30 Jan 2026

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

[+1]

NCT07226986

/ RecruitingPhase 1/2

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment.

Start Date19 Dec 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with Enzalutamide

Login to view more data

100 Translational Medicine associated with Enzalutamide

Login to view more data

100 Patents (Medical) associated with Enzalutamide

Login to view more data

3,842

Literatures (Medical) associated with Enzalutamide

01 Jun 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Boolean network-based identification of optimal drug combinations for prostate cancer

Article

Author: Datta, Aniruddha ; Kumar, Addanki Pratap ; Bhattacharjee, Pranabesh

Prostate cancer is one of the most common cancers among men in the United States and is a leading cause of cancer-related deaths and the second most common cancer in men worldwide. In this study, we used a Boolean network model to analyze prostate cancer signaling pathways and to identify optimal drug combinations for precision therapy. By integrating publicly available biological signaling pathway data with recent research findings, we developed a comprehensive model that represents protein-protein interactions, gene mutations, and pathway dysregulation. Faults induced by mutations were modeled using the "stuck at 0" or "stuck at 1" fault paradigms, capturing the impact of genetic alterations on pathway behavior. The model was simulated across various drug combinations to determine which therapies could most effectively alleviate the aberrant signaling caused by specific mutations. To quantify therapeutic efficacy, we calculated a Size Difference (SD) score, a metric analogous to Hamming distance, measuring the deviation from normal, for each drug combination and fault scenario. The results revealed that drug combinations involving Berberine, Docetaxel, Olaparib, and Enzalutamide showed promising prediction efficacy (more than 90 %), indicating higher therapeutic potential. A distinguishing feature of this work is that, in addition to the standard prostate cancer drugs, we have included Berberine, a non-toxic natural compound with beneficial effects. These computational findings provide a framework for future experimental and clinical validation, which is necessary to confirm the therapeutic relevance of the predicted drug combinations.

01 Apr 2026·ANIMAL REPRODUCTION SCIENCE

Dihydrotestosterone binding to the androgen receptor inhibits apoptosis in ovine undifferentiated granulosa cells via AMH signaling

Article

Author: Liu, Haijiang ; Zhao, Yufen ; Li, Haijun ; Mu, Zhe

Although dihydrotestosterone (DHT), androgen receptor (AR), and anti-Müllerian hormone (AMH) play key roles in ovarian function, their precise contributions and synergistic roles in mammalian follicular development remain unclear. In this study, we first evaluated whether ovine granulosa cells (GCs) undergo differentiation during vitro culture and then determined methods for inhibiting differentiation. Following the culture of GCs with DHT (10^-7 mol/L) and the AR antagonist enzalutamide (ENZ) (10^-6 mol/L) separately or in combination for 48 h, an apoptosis assay revealed that the interaction between DHT and AR decreases sheep GC apoptosis. DHT significantly increased the AMH concentration through AR signaling. In addition, DHT and AR significantly increased the intracellular AMH level, and the use of rAMH (70 pg/mL), a sheep recombinant AMH, significantly upregulated the expression of the BCL2 mRNA in GCs. In summary, GCs undergo spontaneous differentiation during in vitro culture, and the use of the specific luteinizing hormone receptor (LHR) antagonist BAY-899 to inhibit their differentiation establishes an in vitro culture model that maintains GC characteristics. Thus, the interaction between DHT and AR may be involved in the accumulation of AMH signals, affecting GC apoptosis. We provide new mechanistic insights into the roles of DHT and AR in attenuating sheep GC apoptosis. The finding that potential cross-points between DHT/AR-induced intracellular signals affect GC apoptosis will help elucidate the mechanisms regulating early follicular development.

01 Mar 2026·BIOCHEMICAL PHARMACOLOGY

Imperatorin induces ferroptosis via mediating lipid peroxidation and SLC7A11/ACSL4/GPX4 signaling for inhibition and therapeutics of prostate cancer

Article

Author: Jian, Jingang ; Wang, He ; Lin, Yuxin ; Shi, Xiaofeng ; Huang, Yuhua ; Zhang, Jun ; Hou, Jianquan ; Wei, Xuedong ; Xu, Yuefan ; Xu, Haodong

Prostate cancer (PCa) remains a leading cause of cancer-related death among males worldwide. Targeting ferroptosis has now emerged as a promising strategy against cancer. This study aims to deciphering the anti-tumor role of imperatorin, a natural furanocoumarin, in mediating ferroptosis-induced mechanisms for PCa inhibition and treatment. Cell-based assays, including CCK-8, EdU, colony formation, migration, and invasion assays, were used to evaluate the effects of imperatorin on cellular malignant phenotypes. RNA sequencing and bioinformatics analyses identified ferroptosis-related marker signatures, i.e., SLC7A11, ACSL4 and GPX4, were key targets of imperatorin, which were functionally validated using experimental approaches to establish its binding role of ferroptosis, clarify drug specificity, and support translational relevance. It is showed that imperatorin inhibited proliferation, migration, and invasion of PCa cells in a dose-dependent manner by triggering ferroptosis with a potential mechanism of inducing lipid peroxidation via downregulating SLC7A11/GPX4 and upregulating ACSL4. In particular, a significant decreased level of TRIM21-mediated ubiquitination was detected in ACSL4 after imperatorin treatment. Moreover, imperatorin exhibited a synergistic effect with Enzalutamide in vitro, highlighting it as a latent medication strategy for combination therapy. In vivo characterization further demonstrated that imperatorin reduced tumor growth and altered the expression of ferroptosis marker signatures with favorable safety on vital organs from toxicity. This study revealed the ferroptosis-induced power of imperatorin, indicating it as a novel therapeutic candidate against PCa resistance. Future pharmacological and clinical analyses will be conducted for translational understanding of the findings to personalized PCa management.

710

News (Medical) associated with Enzalutamide

26 Jan 2026

·www.pharmaceutical-technology.com

NICE greenlights Pfizer’s Talzenna for NHS use

The UK health watchdog has changed its stance on Pfizer’s Talzenna, now recommending the once-daily drug for NHS use. Image credit: NMK-Studio via Shutterstock.com. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Talzenna (talazoparib) in a step forward for patients in England with prostate cancer. Following the NICE’s decision on 23 January, the once-daily pill will be available to patients with metastatic prostate cancer through the National Health Service (NHS) – adding to its previous recommendation for the drug’s use in metastatic breast cancer . NICE is recommending Talzenna’s use when taken alongside hormonal therapy Xtandi (enzalutamide). Talzenna-Xtandi is specifically indicated for patients with prostate cancer who are not eligible to receive treatment with standard of care (SoC) hormonal therapy plus corticosteroid combinations such as abiraterone-prednisolone. This recommendation marks a shift in stance for NICE, which provisionally stated last year it would not support the drug’s use in prostate cancer. However, the UK health watchdog has since reconsidered its position based on the outcome of a public consultation. Talzenna is a poly-ADP ribose polymerase (PARP) inhibitor that acts by blocking the repair of single-strand breaks in cancer cells, causing genomic instability and cancer cell death. According to Helen Knight, director of medicines evaluation at NICE, the Talzenna recommendation is an “important step forward” for patients with prostate cancer – particularly for those who are unable to receive treatment with chemotherapy or other commonly used medicines. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Knight also touted Talzenna-Xtandi’s at-home administration, which provides a “convenient and flexible” treatment option for patients. The Institute of Cancer Research welcomed the news, stating: “The recommendation marks an important step forward in giving people more treatment options – especially those who cannot undergo chemotherapy. Patients can take the once-daily pill at home, offering convenience and flexibility.” Talzenna is one of three drugs for prostate cancer treatment to recently secure NICE approval, with Bayer and Orion’s oral androgen receptor therapy Nubeqa (darolutamide) and Zytiga (abiraterone) plus its generics being recommended for NHS use in October 2025. The combination therapy first gained US regulatory approval alongside androgen receptor inhibitor Xtandi in prostate cancer in 2023 while the European Commission (EC) approved Talzenna-Xtandi in 2024. Talzenna faces competition in prostate cancer market While the NICE’s decision is a win for Pfizer, Talzenna is part of a competitive metastatic prostate cancer market. This includes AstraZeneca’s PARP inhibitor Lynparza (olaparib), which GlobalData estimates will bring in global sales of $3.5bn at its sales peak across all indications in 2027. However, the drug’s market exclusivity expires in 2027, leaving it vulnerable to generic competition. GSK’s PARP inhibitor Zejula (niraparib) is also a strong market contender, with GlobalData estimating that the drug will generate $791m in global sales at its 2027 peak. Pharma & Schweiz’s Rubraca (rucaparib) also cemented itself in the US market recently, as the PARP inhibitor gained full approval from the US Food and Drug Administration (FDA) in late December 2025. Pharma & Schweiz previously acquired the drug from Clovis Oncology for up to $135m as the latter company looked to sell its assets amid Chapter 11 bankruptcy. GlobalData forecasts that Rubraca will make $139m at its 2029 sales peak in prostate cancer. GlobalData, parent company of Pharmaceutical Technology , forecasts that Talzenna will make global sales of $636m in 2031.

Drug ApprovalAcquisition

26 Jan 2026

·www.icr.ac.uk

ICR welcomes NICE recommendation of talazoparib for advanced prostate cancer

The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in combination with enzalutamide, for adults with prostate cancer that has spread. The judgement makes this new drug combination available for around 2,400 patients in England who cannot take standard treatments and for whom chemotherapy is not suitable. The recommendation marks an important step forward in giving people more treatment options – especially those who cannot undergo chemotherapy. The once-daily pill can be taken at home, offering convenience and flexibility for patients. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research (ICR) and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, led the first-in-human talazoparib trial as well as the phase II TALAPRO-1 trial, which showed that talazoparib could kill prostate cancer cells and prevent its growth. The trial demonstrated the effectiveness and tolerability of the drug for the first time in prostate cancer. The follow-up phase III trial, TALAPRO-2, tested the drug in combination with enzalutamide, with results providing the basis for the NICE recommendation. Talazoparib is a PARP inhibitor – it blocks an enzyme that repairs damaged DNA in certain cancer cells. Cancer cells with DNA repair gene faults – such as BRCA, ATM or PALB2 – already have a defective DNA repair system. By using a drug to block PARP, which helps repair DNA when it is damaged, cancer cells are unable to repair themselves. Twenty years ago, a team of ICR researchers first discovered that PARP inhibitors could be used to target BRCA-mutated cancers. Together with The Royal Marsden, researchers at the ICR including Professor Johann de Bono trialled a PARP inhibitor called olaparib in patients with breast and prostate cancer containing DNA repair gene faults. A team of ICR researchers, led by Professor Alan Ashworth and Professor Chris Lord in the Breast Cancer Now Toby Robins Research Centre, first described talazoparib and explained how it works in 2013. Researchers at the ICR then led the first trials of the drug in humans, in 2017. The drug now joins olaparib as one of the first genetically targeted treatments for prostate cancer. As a targeted therapy, it is a much kinder option for patients than chemotherapy. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “There is an urgent need for effective treatment options after hormonal therapies have stopped working against advanced prostate cancer. The approval of talazoparib will provide another treatment option for these men. The pill can be taken at home, and it comes without many of the side effects of chemotherapy. “In our TALAPRO-1 trial, we showed that talazoparib – a type of PARP inhibitor – kills prostate cancer cells and puts this into remission, especially in men whose tumours have faults in DNA repair genes such as BRCA mutations. The follow-up trial, TALAPRO-2, provided the basis of today’s decision.”

Phase 3Clinical ResultPhase 2Drug Approval

23 Jan 2026

·firstwordpharma.com

NICE U-turn allows NHS funding of Pfizer's Talzenna for prostate cancer

Having recently widened access to abiraterone, the National Institute for Health and Care Excellence (NICE) on Friday issued another decision that will benefit prostate cancer patients in the UK, this time backing use of Pfizer's Talzenna (talazoparib) for those with advanced disease. The recommendation comes a matter of months after the cost-effectiveness body also issued a positive assessment of Bayer's Nubeqa (darolutamide).NICE's ruling on Talzenna represents something of a U-turn, having published draft guidance last August against use of the oral PARP inhibitor with Pfizer and Astellas' androgen receptor signalling inhibitor Xtandi (enzalutamide) for untreated hormone-relapsed metastatic prostate cancer in adults when chemotherapy is not clinically indicated. At the time, NICE noted that the available evidence — which included indirect comparisons with standard treatments such as Xtandi alone or abiraterone plus prednisolone — does not suggest that the combination is value for money in this population.However, NICE said Friday that Talzenna is now recommended, alongside Xtandi, for adults with prostate cancer that has spread. Specifically, Pfizer's once-daily drug is recommended for people where chemotherapy is not suitable and who cannot tolerate or take abiraterone plus prednisolone.Study results showed that in people taking Talzenna with Xtandi, overall survival was 45.8 months compared with 37 months for those on Xtandi alone. The time people lived without their cancer getting worse also increased: 33.1 months compared with 19.5 months. Helen Knight, director of medicines evaluation at NICE, said the combination of Talzenna plus Xtandi "can be taken at home, so provides a convenient and flexible treatment option for people who can't have chemotherapy and are not able to take other medicines so have limited treatment options." NICE noted that this will also reduce pressure on the National Health Service (NHS).The cost-effectiveness body indicated that a confidential commercial arrangement is in place to provide Talzenna to the NHS at a discounted price.

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Enzalutamide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10218	Enzalutamide	L02BB04	DB08899

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	South Korea	Astellas Pharma Korea, Inc.	03 Dec 2024
Castration-sensitive prostate cancer	United States	Astellas Pharma US, Inc.	16 Nov 2023
HRR Gene-mutated Castration-Resistant Prostate Cancer	United States	Pfizer Inc.	20 Jun 2023
Metastatic Prostate Carcinoma	Japan	Astellas Pharma, Inc.	29 May 2020
Castration-Resistant Prostatic Cancer	European Union	Astellas Pharma Europe Ltd.	21 Jun 2013
Castration-Resistant Prostatic Cancer	Iceland	Astellas Pharma Europe Ltd.	21 Jun 2013
Castration-Resistant Prostatic Cancer	Liechtenstein	Astellas Pharma Europe Ltd.	21 Jun 2013
Castration-Resistant Prostatic Cancer	Norway	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	European Union	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	Iceland	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	Liechtenstein	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	Norway	Astellas Pharma Europe Ltd.	21 Jun 2013
Metastatic castration-resistant prostate cancer	United States	Astellas Pharma US, Inc.	31 Aug 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Triple-Negative Breast Carcinoma	Phase 3	United States	Pfizer Inc.	01 Sep 2016
Advanced Triple-Negative Breast Carcinoma	Phase 3	United States	Astellas Pharma, Inc.	01 Sep 2016
Advanced Triple-Negative Breast Carcinoma	Phase 3	United States	MediVation, Inc.	01 Sep 2016
Adenocarcinoma of prostate	Phase 3	United States	Astellas Pharma US, Inc.	22 Jan 2014
Adenocarcinoma of prostate	Phase 3	United States	MediVation, Inc.	22 Jan 2014
Adenocarcinoma of prostate	Phase 3	Canada	MediVation, Inc.	22 Jan 2014
Adenocarcinoma of prostate	Phase 3	Canada	Astellas Pharma US, Inc.	22 Jan 2014
Recurrent Prostate Carcinoma	Phase 3	United States	MediVation, Inc.	22 Jan 2014
Recurrent Prostate Carcinoma	Phase 3	United States	Astellas Pharma US, Inc.	22 Jan 2014
Recurrent Prostate Carcinoma	Phase 3	Canada	Astellas Pharma US, Inc.	22 Jan 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02319837 (EMBARK, Pubmed \| J Urol)	Phase 3	Non-metastatic prostate cancer	468	Enzalutamide plus leuprolide	ojyoybtisn(fvtjcqiwbt) = tvxuhvymjj dcdoyzzxxx (itcthkgmir, 83.0 - 90.4) View more	Positive	17 Dec 2025
				Enzalutamide monotherapy	ojyoybtisn(fvtjcqiwbt) = vfdawologg dcdoyzzxxx (itcthkgmir, 85.6 - 92.4) View more
NCT03751436 (Pubmed \| Cancer Chemother Pharmacol)	Phase 1	Metastatic castration-resistant prostate cancer BCL-2	10	Enzalutamide (160 mg/d) with Venetoclax (metastatic castration-resistant prostate cancer)	xybmowtynb(jnlroefstu) = mrrcmrvyxt nbpbvdjexa (fokgwccedv, 1 - 35) View more	Positive	01 Dec 2025
NCT02203695 (SALV-ENZA, CTgov)	Phase 2	Non-metastatic prostate cancer \| Adenocarcinoma of prostate	86	Enzalutamide (SRT Plus Enzalutamide)	pshtpezmpi = xxjpbdoqqd xiyudtaxsv (aohkoezdbj, elpdxlbvov - dzbinzwkde) View more	-	24 Oct 2025
				SRT (SRT Plus Placebo)	pshtpezmpi = narsqkyfmm xiyudtaxsv (aohkoezdbj, jyxooiveqn - hbbsleplir) View more
NCT02319837 (EMBARK, N Engl J Med \| Company_Website \| ESMO2025) Manual	Phase 3	Non-metastatic prostate cancer	1,068	Enzalutamide + Leuprolide	jykresvktn(tpbdmkkupb) = vvoebscvpl xpcjjupcih (cofemmllzr, 73.9 - 83.1)	Positive	19 Oct 2025
				Enzalutamide monotherapy	jykresvktn(tpbdmkkupb) = cepvvvrgzr xpcjjupcih (cofemmllzr, 67.6 - 77.9)
NCT02319837 (EMBARK, Pubmed \| N Engl J Med)	Phase 3	Non-metastatic prostate cancer	823	Enzalutamide plus leuprolide	espakhsion(boybzyuhou) = onfizjuodo xzercrzlje (bdsrmqsyfy, 73.9 - 83.1)	Positive	19 Oct 2025
				Leuprolide alone	espakhsion(boybzyuhou) = makpkunpyv xzercrzlje (bdsrmqsyfy, 64.0 - 74.3)
ESMO2025	Not Applicable	Castration-sensitive prostate cancer	455	Darolutamide + Docetaxel	podpsljkru(mnedwivbem) = yrfklemcfv kltqrbjvjt (lnjkbsdmtk )	Positive	17 Oct 2025
				Apalutamide	podpsljkru(mnedwivbem) = kxueefbqnm kltqrbjvjt (lnjkbsdmtk )
NCT02319837 (EMBARK, ESMO2025)	Phase 3	Non-metastatic prostate cancer	1,068	Enzalutamide + Leuprolide	ffodamaruz(pzgykrtjzg): HR = 0.597 (95.0% CI, 0.444 - 0.804), P-Value = 0.0006 View more	Positive	17 Oct 2025
				Leuprolide
NCT02446405 (ENZAMET, ESMO2025)	Phase 3	Hormone-dependent prostate cancer	1,125	Docetaxel + Enzalutamide	ozzkqrzkvi(aqjjfvcehq): HR = 1.02 (95.0% CI, 0.92 - 1.12), P-Value = 0.72	Negative	17 Oct 2025
				No Docetaxel + Enzalutamide
NCT02319837 (EMBARK, ESMO2025)	Phase 3	Prostatic Cancer	1,138	Enzalutamide + Leuprolide	hbkjglhpgk(smilpqoofc) = umthaydemf llhmxnipbf (uatbihnlpx ) View more	Positive	17 Oct 2025
				Leuprolide	hbkjglhpgk(smilpqoofc) = iaxamfexsz llhmxnipbf (uatbihnlpx ) View more
NCT00268476 (STAMPEDE, ESMO2025)	Phase 3	Hormone-dependent prostate cancer	6,292	ADT alone (M0)	rttfrjmnzj(fqavykrpkf) = qkrkbddrpx grxowyizqh (pryggruphn, 12 - 22) View more	Negative	17 Oct 2025
				ADT alone (M1)	rttfrjmnzj(fqavykrpkf) = rzealzqsnq grxowyizqh (pryggruphn, 5 - 10)